drugset / Trial / NCT04499209

Pharmacokinetics Study of XG005 Capsule

NCT04499209

Phase 1 Completed 50 enrolled Xgene Pharmaceutical Group
RandomizedParallel-groupDouble-blindBasic science

Summary

This was a Phase 1, single-center, randomized, placebo-controlled, 2-period, ascending single-dose study assessing the PK, safety, and tolerability of single ascending doses of XG005 (Period 1) and the naproxen and pregabalin combination (Period 2), in 5 dose groups each with 10 subjects.

Timeline

Start
2017-10-16
Primary completion
2018-01-18
Completion
2018-03-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule
Comparator Pregabalin Small molecule
Subject XG005 Unknown Oral

Indications

No indication recorded.